Yahoo
Warsaw - Delayed Quote PLN

Mabion S.A. (MAB.WA)

7.90 -0.02 (-0.25%)
At close: October 30 at 5:00:31 PM GMT+1
Chart Range Bar
Loading chart for MAB.WA
  • Previous Close 7.92
  • Open 7.99
  • Bid 7.89 x --
  • Ask 7.90 x --
  • Day's Range 7.85 - 8.05
  • 52 Week Range 6.70 - 10.00
  • Volume 14,069
  • Avg. Volume 33,164
  • Market Cap (intraday) 127.682M
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) --
  • EPS (TTM) -3.51
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.

www.mabion.eu

199

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

MAB.WA
13.18%
MSCI WORLD (^990100-USD-STRD)
9.06%

1-Year Return

MAB.WA
6.06%
MSCI WORLD (^990100-USD-STRD)
9.89%

3-Year Return

MAB.WA
53.20%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

MAB.WA
89.67%
MSCI WORLD (^990100-USD-STRD)
53.16%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY25
Revenue 2.72M
Earnings -15.26M
Profit Margin -561.67%

Q2

FY24

Q3

FY24

Q4

FY24

Q1

FY25

-10M
0
10M
20M
-3000.0%
-2000.0%
-1000.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.67%

  • Return on Equity (ttm)

    -107.92%

  • Revenue (ttm)

    17.61M

  • Net Income Avi to Common (ttm)

    -56.62M

  • Diluted EPS (ttm)

    -3.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.79M

  • Total Debt/Equity (mrq)

    134.30%

  • Levered Free Cash Flow (ttm)

    -17.43M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: